Carbon monoxide (CO), a product of heme metabolism by heme-oxygenase (HO), has biological actions similar to those of nitric oxide (NO). The role of CO in decreasing vascular responses to constrictor agents produced by experimental cirrhosis, induced by carbon tetrachloride (CCl 4 ), was evaluated before and after inhibition of HO with tinmesoporphyrin (SnMP) in the perfused superior mesenteric vasculature (SMV) of cirrhotic and normal rats and in normal rats transfected with the human HO-1 (HHO-1) gene.
JPET #57315 5 HO inhibitors decreased the diameter of pressurized vessels (Kozma, 1999) , likely by inhibiting potassium channels as a result of decreased CO production as has been reported for the thick ascending limb in response to inhibition of HO (Liu, 1999) .
Mesenteric arteriolar vasodilatation and increased portal inflow play a major role in the development of portal hypertension in cirrhosis (Vorobioff, 1984; Shah, 1998) . Various vasodilator compounds including glucagon, adenosine, prostacyclin, NO, α-calcitonin generelated peptide, and adrenomedullin have been proposed as mediators of the mesenteric vascular abnormalities that occur both in cirrhosis and in prehepatic portal hypertension (Shah, 1998; Gatta,1999) . In cirrhotic rats, inhibition of NO synthesis greatly reduced mesenteric blood flow and hyporeactivity of the mesenteric circulation to vasoconstrictor agents (Sieber, 1993) . In rats with prehepatic portal hypertension, HO inhibition modified the hyporeactivity of the mesenteric circulation to vasoconstrictors (Fernandez, 2001 ).
The present study was designed to determine whether: 1) Augmentation of HO contributes to mesenteric vascular abnormalities in cirrhotic rats; 2) Gene transfer reproduces these alterations in normal rats; 3) NOS-NO and HO-CO systems interact in the mesenteric circulation to affect vascular tone and reactivity. To achieve these goals, the isolated perfused superior mesenteric vasculature (SMV) was studied in terms of: 1) Reactivity to JPET #57315 6 to constrictor agents as modified by successive inhibition of CO and NO production, and then reversing the order of inhibition, NO preceding CO. We were able to identify a significant component of each system, nitric oxide synthase (NOS)- NO and HO-CO, that contributed to the vascular hyporeactivity of cirrhotic rats, suggesting "complementary and possibly coordinated physiological roles" (Zakhary, 1996) for CO and NO. Our results indicate a key role for HO in the control of the mesenteric circulation as inhibition of HO activity with SnMP normalized mesenteric perfusion pressure and restored towards normal the response of the mesenteric vasculature to vasoconstrictor agents. We also found, quite unexpectedly, an increase in HO-2, the constitutive enzyme rather than HO-1, the inducible enzyme in the SMV in cirrhotic portal hypertension. Finally, HO activity augmented by HO-1 gene transfer, decreased mesenteric perfusion pressure and reduced the reactivity of the SMV to vasoconstrictor agents. This article has not been copyedited and formatted. The final version may differ from this version. 
MATERIALS AND METHODS

Materials
Phenylephrine (PE) was purchased from Sigma Chemical Co., St. Louis, MI, and dissolved in distilled water. Endothelin-1 (ET-1) was purchased from Peninsula Laboratories, Belmont, CA, and dissolved and stored in 0.1% acetic acid at -20 o C. Stannous-mesoporphyrin (SnMP) was purchased from Porphyrin Products, Inc. Utah, USA. N G -nitro-L-arginine methyl ester (L-NAME) was purchased from Sigma Chemical Co., St. Louis, MI, and dissolved in distilled water.
Animals
Adult male Sprague-Dawley rats (150-160 g b.w.) were purchased from Charles River Laboratories Inc, Wilmington, MA, and housed in an animal facility with controlled normal day-night cycle. The rats were maintained on a standard diet of Purina chow and were allowed free access to water and food until the night before experiments. Experiments were performed in accordance with the guidelines set forth by The American Physiological Society for ethical treatment of animals.
JPET #57315 8 one week prior to conducting experiments. Rats on phenobarbital during the time of treatment were used as controls. Free access to standard chow was allowed throughout the study. In all the CCl 4 -treated rats used for study, portal pressure was measured by a Statham transducer after direct cannulation of the portal vein before the experiments; rats with portal pressure < 8 mmHg were excluded from the study.
Perfusion of isolated mesenteric artery (MacGregor preparation)
The superior mesenteric artery was cannulated with a PE-60 catheter and perfused with 25 ml of warm Krebs-Hanseleit buffer. After the superior mesenteric artery was isolated with its mesentery, the gut was excised near its mesenteric border. The mesenteric arterial bed was then brought in a 37°C water-jacketed container and perfused at a constant rate of 0.8 ml/min/100g b.w. with oxygenated (95% O 2 , 5% CO 2 ) Krebs-Henseleit solution (NaCl 118.5 mmol/L; KCl 4.7 mmol/L; CaCl 2 2.5 mmol/L; KH 2 PO 4 1.2 mmol/L; MgSO 4 1.2 mmol/L; NaHCO 3 25.0 mmol/L; dextrose 11.1 mmol/L; pH 7.4 at 37°C. The effluent was constantly collected, and the pressure measured by a Statham transducer.
Vascular responses to agonists and antagonists
After an initial 30-minute basal period, concentration-response curves were constructed with potassium chloride (KCl), -5.22 to -3.6 log mol, PE, -9.3 to -6.3 log mol, and ET-1, -11.7 to -10.5 log mol, in the presence and absence of HO inhibition with SnMP (10 µM). This concentration of SnMP does not inhibit NOS activity nor activity of soluble guanylate cyclase (Meffert, 1994; Zakhary, 1996) . It does, however, inhibit completely the increase in HO activity produced by either heme or SnCl 2 in endothelial cells as well as smooth muscle cells (Li Volti, 2002) . SnMP was added to the buffer 10 min before vasopressors were This article has not been copyedited and formatted. The final version may differ from this version. perfusion pressure returned to baseline values in 2-3 min after KCl and PE and after 10-15 min after ET-1. Increasing doses were added after return to the baseline pressure.  Experiments performed to determine the differential effects of inhibition of HO and NOS in cirrhotic animals were done using single doses of PE, -7.3 log mol. After the initial equilibration period, the responses to PE were evaluated without inhibitors, and then after inhibition of HO with SnMP (10 µM) (n= 6) or L-NAME (100 µM) (n= 6). After restoration of baseline conditions, the second inhibitor was added to the perfusate and responses to the agonists were again evaluated. L-NAME was dissolved in saline. In rats transfected with the HHO-1 gene, the vasoconstrictor responses of the SMV to PE, -8 log mol, were evaluated after an equilibration period, before and after inhibition of HO with SnMP (10 µM).
Western blot analysis
For the detection of HO-1 and HO-2 protein, microsomes were prepared from tissues as previously described (Sacerdoti,1988) 
Microassay for measurement of HO activity
HO activity was measured as previously described (Chernick, 1989) . Briefly, tissue homogenates (100 µg protein) were incubated in a NADPH generating system, MgCl 2 20 µM, heme 30 µM and 1µCi/ml of 14 C-heme. HO activity was measured as the conversion of heme to bilirubin in the presence of biliverdin reductase. 14 C-bilirubin was extracted with chloroform and radioactivity was measured. Results were expressed as cpm/mg protein.
Construction of the Adenovirus vector containing human HO-1 cDNA
HHO-1 cDNA with adenovirus vector was constructed using a mammalian transfection kit (Stratagene; La Jolla, CA), previously described by Abraham, (1995b) . Briefly, the human cDNA plasmid was constructed as follows: a Xho1-Xba1 fragment of a HHO-1 expression vector, pRc/CMVHO-1, was cloned between Xho1 and Xba1 of the pBacPAC8 to generate pBacPAC8 HHO-1. The Bg1II-BamH1 fragment of the pBacPAC8HHO was then introduced into the Bg1II site of pAdBg1II. The human embryonic cell line, 293 cells (ATCC#1573-CRL), was co-transfected with 10 µg of EcoR1-digested adenoviral HHO-1 and 1 µg of Cla1-digested dL7001DNA by calcium phosphate co-precipitation, using a mammalian transfection kit. HHO-1 adenovirus construct was replicated and encapsulated into an infectious virus as described (Abraham, 1995a) . 
In vivo gene transfer
Eight rats were injected intracardiacally with HHO-1 adenovirus suspension (10 12 pfu/300g b.w.). Four rats were treated with the adenovirus without the HO-1 gene. The animals were acclimatized for one week prior to the start of the experiment, and experiments were performed one week after viral administration. Hemodynamic studies were performed as described above in 6 rats treated with the gene and 4 rats treated with the empty virus.
RNA extraction and RT-PCR
SMV were homogenized in liquid nitrogen and total RNA was extracted with guanine thiocynate, first purified with phenol-chloroform followed by an additional purification with chloroform, and then precipitated with isopropanol (Chomczynski and Sacchi, 1987) . Total RNA was resuspended in autoclaved diethyl pyrocarbonate-water and quantified using Beckman DU7400 spectrophotometer. To verify the quality of RNA, 10 µg of total RNA 
Statistical analysis
Results were expressed as means ± SEM. Concentration-response data for PE and KCl derived from each vessel were fitted separately to a logistic function by non-linear regression and the maximum asymptote of the curve (R max ) and concentration of agonist producing 50%
of the maximal response (EC 50 ), which was expressed as negative log mol, were calculated using commercially available software (Prism 2.01, GraphPAD Software, San Diago, CA).
Concentration-response data were analyzed by two-way analysis of variance. Differences 
RESULTS
We examined the effects of inhibition of HO on perfusion pressure in the isolated perfused SMV obtained from normal and cirrhotic rats. We addressed the effects of inhibition of HO with SnMP (10 µM) on responses of mesenteric arteries to three vasopressor agents: KCl, PE and ET-1. Figure 1 shows the baseline perfusion pressure in normal and cirrhotic rats with and without SnMP. Mesenteric perfusion pressure was lower in cirrhotic than in normal rats (p<0.05). Further, inhibition of HO did not significantly increase (6 ± 3 %) mesenteric perfusion pressure in control animals (n=14), whereas in cirrhotic rats a significant increase in pressure of 20 ± 3 % was observed (n=14).
Next we examined whether inhibition of HO by SnMP (10 µM) can restore normal vasopressor responses to KCl, PE, and ET-1 which were depressed in cirrhotic animals. The vasoconstrictor responses to KCl, PE, and ET-1 were shifted to the right, the maximal response was blunted, and the EC 50 for KCl was increased (Figures 2-4) . SnMP significantly increased the response to KCl in normal (n=8) and in cirrhotic rats, and restored to normal the responsiveness to KCl in the SMV (n=8) (Figure 2 ). SnMP did not affect the vasoconstrictor response to the sympathomimetic agent, PE, in normal rats (n=8) and restored to normal the responses of the SMV to the vasoconstrictor agent in cirrhotic rats (n=8) (Figure 3) . SnMP increased the vasoconstrictor responses of SMV to ET-1 in cirrhotic, but not in normal rats (n=8); in cirrhotic rats, the responses to ET-1 in SMV were restored to normal (n=8) (Figure 4 ). These results indicate that SnMP-induced inhibition of HO in cirrhotic rats restores towards normal the responsiveness of the SMV to vasopressor agents.
This article has not been copyedited and formatted. The final version may differ from this version. We also examined the contributions of NO and CO to attenuating the response to PE in the SMV in view of reports that NO contributes to hyporeactivity of the SMV to pressor agents in cirrhotic rats (Sieber, 1993) . SnMP was used to inhibit HO because of its demonstrated selectivity at the concentration employed (10 µM) and its solubility (Zakhary, 1996) . It was important that SnMP did not inhibit NOS as our study was directed at the vascular effects of CO in the SMV of cirrhotic rats. The relative contribution of HO-CO and NOS-NO to producing hyporeactivity of the SMV of cirrhotic rats to PE was assessed by determining the effects of inhibiting each system separately, i.e., HO-CO with SnMP and NOS-NO with L-NAME, followed by inhibition of the other system, then reversing the order of inhibition of CO and NO production ( Figure 5A and B). After achieving a significant reduction in vascular hyporeactivity by inhibition of either HO or NOS, additional reduction was obtained on inhibiting the other gas-producing system. For example, in Figure 5A , the constrictor response of the SMV of cirrhotic rats to PE was increased by inhibition of HO activity with SnMP and was further enhanced by inhibition of NOS activity with L-NAME.
Then, the order of inhibition of HO and NOS activities was reversed in Figure 5B . After the combined inhibition of HO and NOS, the constrictor responses of the SMV of cirrhotic rats to PE were fully restored. Moreover, the effects of either SnMP or L-NAME in restoring to normal the vasoconstrictor responses to PE ( Figure 5 ) in cirrhotic rats, were similar irrespective of the order of administration of SnMP or L-NAME. These findings are in accord with the findings of Thorup (1999) that CO "may synergize with NO in eliciting vasorelaxation and modulating basal vascular tone" by effects on vascular mechanisms as, for example, those served by guanylyl cyclase and cGMP.
This article has not been copyedited and formatted. The final version may differ from this version. We examined whether responsiveness of mesenteric arteries of cirrhotic rats to vasopressor agents was associated with increased expression of HO-1 and HO-2 in this vascular bed.
Western blot analysis of mesenteric blood vessels obtained from normal and cirrhotic rats (Figure 6A ), demonstrated significantly higher levels of HO-2, but not of HO-1, in vascular tissues obtained from cirrhotic rats (lanes 5-8) compared to those from normal rats (lanes 1-4). HO upregulation was quantified by densitometry-based analysis of HO-1 and HO-2 proteins after blotting the ratio of each sample. As seen in the densitometry analysis ( Figure   6B ), HO-2 was increased significantly in SMV obtained from cirrhotic rats when compared to those of control rats.
To assess the effect of the increase in HO-2 protein on HO activity, cell homogenates obtained from SMVs of control and cirrhotic rats were used to measure the enzyme activity as indicated by C 14 heme catabolism to C 14 bilirubin (Figure 7 ). Bilirubin formation was significantly increased in SMV samples obtained from cirrhotic rats compared to those obtained from control rats (p< 0.05). These findings help explain: 1) the hyporeactivity of the mesenteric vasculature to vasoconstrictor agents; and 2) why inhibition of HO helps restore the responsiveness to vasoconstrictor agents of the SMV obtained from cirrhotic animals.
To examine further our hypothesis that increased HO levels in mesenteric arteries in 
DISCUSSION
Portal hypertension, a major complication of cirrhosis, is the basis for the development of esophageal varices, ascites, renal failure, and hepatic encephalopathy (Gatta, 1999) .
Mesenteric arterial resistance is normally high, whereas in cirrhosis, dilatation of the mesenteric vasculature is associated with an increase in portal inflow, a major determinant of portal hypertension (Shah, 1998; Gatta, 1999) . Further, in experimental cirrhosis, the responsiveness of the mesenteric circulation to pressor agents is greatly impaired (Sieber, 1993; Gagano, 1997) . A number of endogenous vasoactive compounds, previously enumerated, has been proposed to mediate this lack of vascular responsiveness (Shah, 1998; Gatta, 1999) .
In the present study, we have shown in rats with CCl 4 -induced hepatic cirrhosis that the resulting attenuation of mesenteric vascular constrictor responses to diverse agonists could be reversed by inhibition of HO, highlighting the potential importance of the HO-CO system to the regulation of circulatory tone and vascular reactivity. Quite unexpectedly, the HO isoform responsible for mesenteric vascular hyporeactivity was shown to be the constitutive enzyme HO-2, not HO-1, the inducible enzyme. This finding is not unique as HO-2 levels are increased by estrogens in endothelial cells (Tschugguel, 2001) We also examined potential interactions of the NOS-NO and HO-CO systems in the mesenteric vasculature in view of the demonstrated contribution of NO to splanchnic vascular hyporeactivity in cirrhotic rats (Sieber, 1993) . Our findings suggest that these systems are complementary in the mesenteric circulation of the cirrhotic rat, which agrees with the "coordinated functions of NO and CO" proposed by Zakhary et al. (1996) and is in accord with the presence in endothelial cells of both NOS and HO (Zakhary, 1996) , as well as the ability of each system to activate soluble guanylate cyclase and increase cGMP (Abraham, 2002) . Alternatively, rather than overlapping spheres of activity of NO-and COmediated vascular effects reflecting colocalization of NOS and HO isoforms in the endothelium, segmental separation within a vasculature --eNOS predominating in large arteries and HO-2 in small arteries and microvessels --may also give rise to coordinated and complementary responses of the NOS-NO and HO-CO systems (Zakhary, 1996) . A recent study demonstrated that, despite eNOS gene deletion, mice with portal hypertension developed a hyperdynamic circulation, indicating the importance of other vasodilator systems in the production of splanchnic circulatory changes in portal hypertensive animals (Iwakiri, 2002) .
The possibility that SnMP inhibits NOS as well as HO under conditions of our study is unlikely as weak inhibition of NOS with SnMP can be obtained only at a 10 times higher concentration (100 µM) than that used in our study (10 µM) (Meffert, 1994; Zakhary, 1996) .
Further, SnMP, in the concentration used in our study (10 µM), was shown to be without effect on eNOS activity in the vasculature despite colocalization of HO-2 and eNOS in the endothelium of the several vascular beds studied (Zakhary, 1996) . This specificity of SnMP relative to HO when compared to NOS has also been reported for the CNS (Meffert, 1994) .
Further, the data presented in Figure 5A and B show that prior administration of SnMP does not notably affect the action of L-NAME in augmenting the constrictor response of the SMV to PE, indicating that the activity of NOS is not, to a readily detectable degree, affected by prior treatment with SnMP under the conditions of our study. Taken together, our findings support a role for HO-CO that may synergize with NOS-NO in regulating the mesenteric circulation; they provide a conceptual basis for examining abnormalities of vascular beds in human hepatic cirrhosis. The systemic circulation, in addition to the splanchnic vasculature, is affected by hepatic cirrhosis associated with a decline in systemic vascular resistance in human subjects (Schrier,1998) associated with increased CO production, the magnitude of which was correlated with the severity of the cirrhosis (De Las Heras, 2003) . Inhibition of HO has also been reported to reverse vascular hyporeactivity to norepinephrine in cirrhotic patients (Sacerdoti, 2002) . CO lowers blood pressure in rats by participating in the regulation of basal tone in resistance blood vessels (Johnson, 1995; Kozma, 1999) . In normal rats, inhibition of HO increased blood pressure 
